Nijmegen, Netherlands, 11 July 2024 – MGI (MGI Tech Co., Ltd. or its subsidiaries, collectively referred to as MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced a collaboration with Predica Diagnostics, a leading innovator in oncology diagnostics, to develop Predica’s targeted RNA sequencing tests on MGI’s cost-effective Next-generation sequencing (NGS) platforms.
The collaboration aims to transform molecular diagnostics by enabling early cancer detection and facilitating personalised, targeted treatment strategies. By combining Predica Diagnostics’ advanced sequencing assays with MGI’s state-of-the-art NGS platforms, the initiative promises rapid, accurate, and affordable solutions for healthcare providers.
Empowering Precision Medicine
Predica Diagnostics, renowned for its expertise in cervical cancer screening through its proprietary ciRNAseq-based test, CervicaDx, brings unmatched precision in identifying high-risk HPV oncogenes and other (pre)malignancy biomarkers. By integrating this diagnostic capability with MGI’s robust and cost-efficient DNBSEQ technology, the partnership aims to significantly enhance the accuracy and accessibility of advanced diagnostic tests.
Enhancing Affordability and Accessibility
A core goal of this partnership is to make high-quality diagnostic and predictive testing more affordable and accessible. MGI Tech’s DNBSEQ platforms, recognised for their cost-efficiency and scalability, enable healthcare institutions to provide advanced genomic and transcriptomic testing at lower costs. Compared to existing NGS technologies, MGI’s platform delivers faster results with reduced operational costs. Within the collaboration, MGI’s platform will perform the final analysis of Predica’s ciRNAseq-based targeted RNA sequencing tests, helping researchers and clinicians better predict patient prognosis and guide precision treatment strategies.
A Shared Vision for the Future
“Predica welcomes MGI as a partner with expertise that complements our own,” said Dr. William Leenders, CSO of Predica Diagnostics. “Where our strength lies in providing smart molecular diagnostic solutions for unmet medical needs, combining it with MGI’s sequencing platforms ensures customers can access clinically critical gene expression information without the need for on-site bioinformatics expertise.”
Dr. Yong Hou, General Manager of MGI Europe and Africa, added, “This partnership reflects our commitment to advancing healthcare through innovative genomic solutions. By combining our affordable, high-performance sequencing technology with Predica’s expert diagnostic kits, we are poised to make a significant impact in personalised medicine.”
About Predica Diagnostics B.V.
Predica Diagnostics, a spinoff from Radboud UMC, operates in diagnostics, prognostics, and prediction of treatment response in oncology. Predica aims to bring its ciRNAseq technology to patients within 1–2 years, initially focusing on the CervicaDx test for improved cervical cancer screening. This non-invasive test enables highly specific detection of cervical abnormalities in women with a positive HPV test. Other tests in development include assays to detect host-microbiome interactions and biological pathway activity, supporting personalised cancer treatment strategies.
